Peregrine Pharmaceuticals, Inc. (PPHM-NASDAQ) just issued a press release showing "Peregrine’s Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model" AND "Shows Peregrine’s Selective Anti-VEGF Antibodies are as Effective as…
Vertex (VRTX-NASDAQ) is seeing quite a bit of trading today ahead of a data presentation tomorrow. This one may have been very active all on its own, but since Dendreon (DNDN-NASDAQ) made its exponential…
Merck’s new arthritis drug Arcoxia was rejected by an FDA panel by a vote of 20-to-1. Apparently, the drug has cardiovascular risks. The same problem with a related drug that company produced, Vioxx, has…
by H.S. AyoubBioHealth Investor.com
Cramer said in a video this afternoon on TheStreet.com that this Dendreon (DNDN-NASDAQ) is a classic case of short sellers not covering themselves by not buying calls with the strikes above. The street.com ran…
MedImmune, Inc. (MEDI-NASDAQ) announced that its board of directors has authorized management to evaluate whether third parties would have an interest in acquiring the company at a price and on terms that would represent…
by H.S. AyoubBioHealth Investor.com
by H.S. AyoubBioHealthInvestor.com
Genetech (DNA-NYSE) posted earnings: $0.74 EPS and revenues were $2.843 Billion; expectations were $0.67 EPS & R$2.74 Billion. The stock is still at the lower end of its recent trading range of 2007. Avastin…
Cell Genesys, Inc. (CEGE-NASDAQ) has done what many small biotechs do that are in need of cash: sell shares in a private placement "PIPE" after a sharp stock run-up. It has entered into definitive…
Dendreon (DNDN-NASDAQ) is trading down more than 4% at $21.25 in early trading after JMP Securities downgraded the shares. DNDN closed down 6% at $22.15 yesterday . The “official” rating was cut from a…
by H.S. AyoubBioHealth Investor.com
Amgen (AMGN-NASDAQ) is naming a new CFO. Robert Bradway is replacing Richard Nanula, who is leaving to pursue other opportunities. Bradway came to Amgen in 2006 and prior to that he was with Morgan…
Adolor Corp. (ADLR-NASDAQ) may have just joined the ranks of current and future biotech zombies. The company suspended its lead new drug candidate for potential treatment of opioid-induced bowel dysfunction. Safety concerns prompted the…
by H.S. AyoubBioHealth Investor.com